Toronto Stock Exchange Symbol: MS
EDMONTON, Feb. 5 /CNW/ - BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that
Mr. Kevin Giese, President and CEO, will present at The 11th Annual BIO CEO &
Investor Conference in New York.
WHEN: Monday February 9th at 2:45pm (Eastern Time)
WHERE: Waldorf-Astoria, New York City
About BIO CEO & Investor Conference
This conference aims to bring together institutional investors, industry
analysts, and senior biotechnology executives in a neutral and collaborative
forum to examine investment opportunities and issues affecting the industry.
For more information visit http://ceo.bio.org/opencms/ceo/2009/index.jsp.
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, dirucotide, is for the treatment of multiple sclerosis and is
being evaluated in two pivotal phase III clinical trials for Secondary
Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the
United States. In December 2007, BioMS entered into a licensing and
development agreement granting Eli Lilly and Company exclusive worldwide
rights to dirucotide in exchange for an $87 million upfront payment, milestone
payments and escalating royalties on sales. For further information please
visit our website at http://www.biomsmedical.com.
This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that dirucotide will continue to demonstrate a satisfactory
safety profile in ongoing and future clinical trials; and that BioMS Medical
Corp. will complete the respective clinical trials within the timelines
communicated in this release. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
For further information:
For further information: Tony Hesby, Ryan Giese, Amanda Stadel, BioMS
Medical Corp., (780) 413-7152, (780) 408-3040 Fax, E-mail:
firstname.lastname@example.org, Internet: http://www.biomsmedical.com; James Smith,
Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail: